Sartorius Stedim Biotech and Penn State University Announce Biotechnology Partnership

News
Article

Sartorius Stedim Biotech will supply equipment for Penn State’s new Fermentation Facility in the university’s Center of Excellence in Industrial Biotechnology.

Sartorius Stedim Biotech and Penn State University have entered into a collaborative partnership to advance multidisciplinary teaching and research in biotechnology, the company and university announced in an April 16, 2018 press release. This long-term relationship will support the education and preparation of the next generation of biotechnology leaders. Part of Sartorius’ investment will be to enhance the Fermentation Facility that will play a significant role in Penn State’s Center of Excellence in Industrial Biotechnology (CoEIB). Sartorius will provide fermentation technologies, and a central laboratory within the Fermentation Facility will be named the Sartorius Fermentation Gallery.

Sartorius views this partnership as an opportunity to create a hub that will promote innovation in biotechnology. “We look forward to bringing together future thought leaders within the new Sartorius Fermentation Gallery,” said Reinhard Vogt, member of Executive Committee of Sartorius Stedim Biotech, in the press release. 

Sartorius, together with additional industry partners, has been supporting Penn State for more than a year in designing the new lab space and in equipping it based on the latest technologies. The Fermentation Facility is one of 10 core facilities in the Huck Institutes of the Life Sciences and the cornerstone of Penn State’s comprehensive biotechnology effort. This effort includes the CoEIB, recently launched with a landmark gift from CSL Behring. The CoEIB provides a focal point for Penn State’s programs in the area of industrial biotechnology, including the development of research and educational initiatives focused, among other areas, on biopharmaceutical manufacturing.

Source: Sartorius Stedim Biotech and Penn State

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content